Immune-related Colitis Induced by the Long-term Use of Nivolumab in a Patient with Non-small Cell Lung Cancer

被引：24
|
作者：
Yasuda, Yuichiro [1 ]
Urata, Yoshiko [1 ]
Tohnai, Rie [1 ]
Ito, Shoichi [1 ]
Kawa, Yoshitaka [1 ]
Kono, Yuko [1 ]
Hattori, Yoshihiro [1 ]
Tsuda, Masahiro [2 ]
Sakuma, Toshiko [3 ]
Negoro, Shunichi [1 ]
Satouchi, Miyako [1 ]
机构：
[1] Hyogo Canc Ctr, Dept Thorac Oncol, Akashi, Hyogo, Japan
[2] Hyogo Canc Ctr, Dept Gastroenterol Oncol, Akashi, Hyogo, Japan
[3] Hyogo Canc Ctr, Dept Diagnost Pathol, Akashi, Hyogo, Japan
来源：
INTERNAL MEDICINE | 2018年 / 57卷 / 09期
关键词：
nivolumab; immune-related adverse event; colitis; non-small cell lung cancer; immune-checkpoint-inhibitor; MANAGEMENT; DOCETAXEL; BLOCKADE;
D O I：
10.2169/internalmedicine.9230-17
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
We herein report a case of immune-related colitis induced by the long-term use of nivolumab. A 62-year-old Japanese man was treated with nivolumab at 3 mg/kg every 2 weeks for advanced lung adenocarcinoma. The patient was admitted to our hospital due to non-bloody watery diarrhea after the 70th dose of nivolumab. A biopsy specimen of the colon mucosa revealed evidence of colitis with cryptitis and crypt microabscesses. He was diagnosed with immune-related colitis and started on predonisolone 60 mg/day. Subsequently, his symptoms remarkably resolved. Consideration of immune-related adverse events up to several years after the initiation of nivolumab is important.
引用
收藏
页码：1269 / 1272
页数：4
相关论文
共 50 条
  • [21] Serious Immune-related Adverse Events Are Associated With Greater Efficacy of Nivolumab Therapy Against Non-small Cell Lung Cancer
    Blazek, Jiri
    Hosek, Petr
    Hrabcova, Karolina
    Bratova, Monika
    Kultan, Juraj
    Hrnciarik, Michal
    Cernovska, Marketa
    Zemanova, Petra
    Krejci, Jana
    Koubkova, Leona
    Stastny, Marek
    Svaton, Martin
    IN VIVO, 2023, 37 (05): : 2229 - 2236
  • [22] Risk factors for severe immune-related pneumonitis after nivolumab plus ipilimumab therapy for non-small cell lung cancer
    Sumi, Toshiyuki
    Sekikawa, Motoki
    Koshino, Yuta
    Nagayama, Daiki
    Nagahisa, Yuta
    Matsuura, Keigo
    Shijubou, Naoki
    Kamada, Koki
    Suzuki, Keito
    Ikeda, Takumi
    Michimata, Haruhiko
    Watanabe, Hiroki
    Yamada, Yuichi
    Osuda, Koichi
    Tanaka, Yusuke
    Chiba, Hirofumi
    THORACIC CANCER, 2024, 15 (20) : 1572 - 1581
  • [23] Immune-Related Adverse Events and Their Effect on Outcomes in Patients (pts) with Non-Small Cell Lung Cancer (NSCLC) Treated with Nivolumab
    Kothari, Shawn
    Bagley, Stephen
    Aggarwal, Charu
    Baum, Joshua
    Alley, Evan
    Evans, Tracey
    Kosteva, John
    Ciunci, Christine
    Thompson, Jeffrey
    Stonehouse-Lee, Susan
    Sherry, Victoria
    Gilbert, Elizabeth
    Eaby-Sandy, Beth
    Mutale, Faith
    Dilullo, Gloria
    Cohen, Roger
    Vachani, Anil
    Langer, Corey
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1290 - S1290
  • [24] Management of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer
    Burke, Michael
    Rashdan, Sawsan
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [25] Peroral cholangioscopy of nivolumab-related (induced) ulcerative cholangitis in a patient with non-small cell lung cancer
    Kuraoka, Naosuke
    Hara, Kazuo
    Terai, Shuji
    Yatabe, Yasushi
    Horio, Yoshitsugu
    ENDOSCOPY, 2018, 50 (09) : E259 - E261
  • [26] USE OF INFLIXIMAB IN THE TREATMENT OF NIVOLUMAB-INDUCED REFRACTORY COLITIS IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER
    Prakash, Ravi K.
    Abboud, Elham
    Gershenhorn, Bruce
    Gupta, Digant
    Vashi, Pankaj G.
    GASTROENTEROLOGY, 2017, 152 (05) : S809 - S810
  • [27] Long-Term Survival in a Patient with Non-Small Cell Lung Cancer Presenting as Small Intestinal Obstruction
    Grenader, Tal
    Goldberg, Anthony
    ONKOLOGIE, 2010, 33 (04): : 178 - 180
  • [28] Consensus on the use of immune-related response criteria to evaluate the efficacy of immunotherapy in non-small cell lung cancer
    M. Provencio
    E. Carcereny
    Á. Artal
    Clinical and Translational Oncology, 2019, 21 : 1464 - 1471
  • [29] Consensus on the use of immune-related response criteria to evaluate the efficacy of immunotherapy in non-small cell lung cancer
    Provencio, M.
    Carcereny, E.
    Artal, A.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (11): : 1464 - 1471
  • [30] Long-term outcomes with nivolumab in patients with previously treated advanced Non-Small Cell Lung Cancer (NSCLC)
    Thomas, M.
    Kohlhaeufl, M.
    Reck, M.
    Engel-Riedel, W.
    Kortsik, C.
    Bullinger, L.
    Schneider, C. -P.
    Felip, E.
    Brahmer, J.
    Vokes, E.
    Gettinger, S.
    Geese, W.
    Yoon, D.
    Healey, D.
    Li, A.
    Eberhardt, W. E. E.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 137 - 137
12345